Join Now

Author Archives: Press Release

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

By Press Release | Published July 10, 2025

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Posted in BioUtah News | Tagged | Comments Off on Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

By Press Release | Published July 10, 2025

FDA assigns PDUFA target action date of January 5, 2026, for decision on accelerated approval.

Posted in Policy News | Tagged | Comments Off on Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

GE HealthCare’s Economic Impact Across Utah

By Press Release | Published July 10, 2025

GE HealthCare’s Economic Impact Across Utah

Posted in BioUtah News | Tagged | Comments Off on GE HealthCare’s Economic Impact Across Utah

RefloDx Wins Trans Atlantic Angel Grand Prize

By Press Release | Published July 10, 2025

RefloDx Wins Trans Atlantic Angel Grand Prize.

Posted in BioUtah News | Tagged | Comments Off on RefloDx Wins Trans Atlantic Angel Grand Prize

bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies

By Press Release | Published June 19, 2025

bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies

Posted in BioUtah News | Tagged | Comments Off on bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies

DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY

By Press Release | Published June 19, 2025

ALPHA-EMITTING RADIOISOTOPE EXPECTED TO PLAY AN ESSENTIAL ROLE IN NEXT-GENERATION TARGETED CANCER THERAPIES

Posted in BioUtah News | Tagged | Comments Off on DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY

Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation

By Press Release | Published June 19, 2025

Completion of SAD/MAD trial marks advancement toward further clinical development of HT-4253 in Alzheimer’s and other neurodegenerative diseases.

Posted in BioUtah News | Tagged | Comments Off on Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation

Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services

By Press Release | Published June 19, 2025

Strategic Expansion in Salt Lake City Headquarters Will Meet Stringent EU GMP Annex 1 Requirements

Posted in BioUtah News | Tagged | Comments Off on Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services

RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS

By Press Release | Published June 19, 2025

AGREEMENT PROVIDES RATIO ACCESS TO NUSANO-PRODUCED RADIOISOTOPES FOR ONCOLOGY DIAGNOSTICS AND THERAPEUTICS

Posted in BioUtah News | Tagged | Comments Off on RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS

Microvascular Therapeutics announces Founder and CEO Dr. Evan Unger as panelist in Commercializing SBIR/STTR Technologies Discussion at BIO 2025

By Press Release | Published June 19, 2025

Microvascular Therapeutics announces Founder and CEO Dr. Evan Unger as panelist in Commercializing SBIR/STTR Technologies Discussion at BIO 2025

Posted in BioUtah News | Tagged | Comments Off on Microvascular Therapeutics announces Founder and CEO Dr. Evan Unger as panelist in Commercializing SBIR/STTR Technologies Discussion at BIO 2025

Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials

By Press Release | Published June 12, 2025

Groundbreaking Preclinical Data Propel Clinical Milestone

Posted in BioUtah News | Tagged | Comments Off on Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials

Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development

By Press Release | Published June 12, 2025

Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development

Posted in BioUtah News | Tagged | Comments Off on Rebel Medicine Announces Series A Financing and Investigational New Drug (IND) Application Opening to Advance Non‑Opioid Pain Therapeutic into Clinical Development

A Special Thanks To Our Elite Members